Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at the ...

for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and ...

for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is an extended-release (ER) dual ĸ-opioid receptor agonist and µ-opioid ...

Low dose morphine has the potential to treat chronic cough in people with idiopathic pulmonary fibrosis (IPF), according to new research from two National Institute for Health and Care ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic ...

September is Pulmonary Fibrosis Awareness Month. Pulmonary fibrosis is a disease marked by scarring in the lungs.